



30 June 2022 Pillar 3 report

UBS Europe SE

# Table of contents

3	Introduction and basis for preparation
5	Key ratios
6	Own funds and eligible liabilities
10	Covid-19 Disclosures

# Introduction and basis for preparation

## Scope of Pillar 3 disclosures

UBS Europe SE is a fully authorized credit institution registered at the commercial register in Frankfurt and supervised by the European Central Bank (ECB). This report provides the disclosure information for UBS Europe SE as at 30 June 2022.

The capital adequacy framework consists of three pillars each of which focuses on a different aspect of adequacy. Pillar 1 provides a framework for measuring minimum capital requirements for credit, market, operational and non-counterparty related risks faced by banks. Pillar 2 addresses the principles of the supervisory review process emphasizing the need for a qualitative approach to supervising banks. Pillar 3 aims to encourage market discipline by requiring banks to publish a range of disclosures, mainly on risk and capital.


This document is based upon the Regulation (EU) 2019/876 and Directive (EU) 2019/878 amending Regulation (EU) 575/2013, Regulation (EU) 648/2012 and Directive (EU) 2013/36, the associated delegated and implementing acts and the related Implementing Technical Standards (ITS), as implemented within the Federal Republic of Germany by the Bundesbank. Further, these disclosures have been prepared in accordance with the respective applicable European Banking Authority (EBA) guidelines.

For disclosures according to Section 26a German Banking Act ("Kreditwesengesetz" or "KWG") please see the respective section in our Annual Financial Statements as of 31 December 2021. For our firm's sustainability approach and activities please see UBS Group AG Sustainability Report 2022.

## Regulatory consolidation

UBS Europe SE is part of the UBS Group AG consolidated group and a direct, wholly owned subsidiary of UBS AG. The scope of regulatory reporting for UBS Europe SE includes the Italian

### Scope of regulatory consolidation



1 Not Established in Germany  
 2 Foreign branches included – Luxembourg, Sweden, Denmark, Italy, Spain, the Netherlands, France, Switzerland and Poland

subsidiary UBS Fiduciaria SpA as well as the Spanish subsidiary UBS Gestión S.G.I.I.C., SA. As the relevant limits according to Article 19 of the CRR are not exceeded, the German subsidiary UBS Private Equity Komplementär GmbH is not included in the regulatory scope of consolidation.

In accordance with the principle of materiality specified in Article 432 of the CRR, this report provides Pillar 3 disclosures for UBS Europe SE on the consolidated basis, including all relevant subsidiaries. In this report, "UBS Europe SE" refers to UBS Europe SE and its consolidated subsidiaries, unless stated otherwise.

## Governance over Pillar 3 disclosures

The Management Board and senior management are responsible for establishing and maintaining an effective internal control structure over the disclosure of financial information, including Pillar 3 disclosures. In line with Article 431 of the CRR, UBS Europe SE has a board-approved Pillar 3 disclosure governance policy in place. This Pillar 3 report has been approved by the Chief Financial Officer of Europe SE, in line with this policy.

The UBS Europe SE Head of Regulatory Reporting formally attests that the disclosures provided in this document meet the requirements of the Part 8 of the CRR in accordance with formal UBS Europe SE policy and company's internal processes, systems and controls.

## Format of Pillar 3 disclosures

The format of disclosures is based upon the respective applicable ITS. The comparative figures represent the latest disclosed period where applicable. Disclosures classified as non-material in accordance with Article 432 of the CRR and BaFin Circular 05/2015 in this report have been indicated accordingly in the respective sections. The table on the following page provides an overview of the Pillar 3 disclosures.

<b>CRR Article</b>	<b>Pillar 3 Requirement</b>	<b>EU Table &amp; Template Reference</b>	<b>Location of Pillar 3 disclosure in this report</b>
437	Own Funds	EU CCA	Own funds and eligible liabilities
437a	Own funds and eligible liabilities	EU ILAC, EU TLAC2A EU CCA	Own funds and eligible liabilities
447	Key metrics	EU KM1	Key Metrics
453	Credit risk mitigation techniques	EBA/GL/2020/07	Covid-19 Disclosures

# Key ratios

The following is a summary of the key ratios of UBS Europe SE in accordance with Article 447 of the CRR.

## EU KM1 - Key metrics

EUR m	30.06.22	31.12.21	30.06.21	31.12.20
<b>Available own funds (amounts)</b>				
Common Equity Tier 1 (CET1) capital	2,427	2,764	3,927	3,703
Tier 1 capital	3,027	3,054	4,217	3,993
Total capital	3,027	3,054	4,217	3,993
<b>Risk-weighted exposure amounts</b>				
Total risk exposure amount	11,412	12,328	13,119	13,175
<b>Capital ratios (as a percentage of risk-weighted exposure amount)</b>				
Common Equity Tier 1 ratio (%)	21.26%	22.42%	29.93%	28.11%
Tier 1 ratio (%)	26.52%	24.77%	32.14%	30.31%
Total capital ratio (%)	26.52%	24.77%	32.14%	30.31%
<b>Additional own funds requirements to address risks other than the risk of excessive leverage (as a percentage of risk-weighted exposure amount)</b>				
Additional own funds requirements to address risks other than the risk of excessive leverage (%)	2.25%	2.50%	2.50%	
<i>of which: to be made up of CET1 capital (percentage points)</i>	1.27%	1.41%	1.41%	
<i>of which: to be made up of Tier 1 capital (percentage points)</i>	1.69%	1.88%	1.88%	
Total SREP own funds requirements (%)	10.25%	10.50%	10.50%	
<b>Combined buffer and overall capital requirement (as a percentage of risk-weighted exposure amount)</b>				
Capital conservation buffer (%)	2.50%	2.50%	2.50%	
<i>Conservation buffer due to macro-prudential or systemic risk identified at the level of a Member State (%)</i>				
<i>Institution specific countercyclical capital buffer (%)</i>	0.09%	0.11%	0.09%	
<i>Systemic risk buffer (%)</i>				
<i>Combined buffer requirement (%)</i>	2.59%	2.61%	2.59%	
<i>Overall capital requirements (%)</i>	12.84%	13.11%	13.09%	
CET1 available after meeting the total SREP own funds requirements(%)	15.50%	14.27%	21.40%	
<b>Leverage ratio</b>				
Total exposure measure	47,364	46,660	47,094	41,376
Leverage ratio (%) <sup>1</sup>	6.39%	6.55%	8.95%	9.65%
<b>Additional own funds requirements to address the risk of excessive leverage (as a percentage of total exposure measure)</b>				
Additional own funds requirements to address the risk of excessive leverage (%)				
<i>of which: to be made up of CET1 capital (percentage points)</i>				
Total SREP leverage ratio requirements (%)	3.00%	3.00%	3.00%	
<b>Leverage ratio buffer and overall leverage ratio requirement (as a percentage of total exposure measure)</b>				
Leverage ratio buffer requirement (%)				
Overall leverage ratio requirement (%)	3.00%	3.00%	3.00%	
<b>Liquidity Coverage Ratio</b>				
Total high-quality liquid assets (HQLA) (Weighted value - average)	19,060	17,143	17,106	
Cash outflows - Total weighted value	33,403	26,184	19,449	
Cash inflows - Total weighted value	21,805	16,135	8,765	
Total net cash outflows (adjusted value)	11,640	10,091	10,684	
Liquidity coverage ratio (%)	166%	170%	161%	151%
<b>Net Stable Funding Ratio</b>				
Total available stable funding	13,853	15,358	15,816	
Total required stable funding	9,343	8,963	9,631	
NSFR ratio (%)	148%	171%	164%	

<sup>1</sup> Referred to as 'Tier 1 leverage ratio' and 'Basel III leverage ratio' in UBS Group report as well as in UBS Group Pillar 3 report, respectively.

# Own funds and eligible liabilities

The table below depicts the main features and terms and conditions of capital instruments issued by UBS Europe SE in accordance with Article 437 of the CRR.

## EU CCA: Main features of regulatory own funds instruments and eligible liabilities instruments

	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Internal total loss-absorbing capacity (TLAC) eligible liabilities				
Issuer	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE
Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Public or private placement	Private	Private	Private	Private	Private	Private	Private	Private
Governing law(s) of the instrument	German	German	German	German	German	German	German	German
Contractual recognition of write down and conversion powers of resolution authorities	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Regulatory treatment								
Transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible
Post-transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible
Eligible at solo/(sub-)consolidated/ solo & (sub-)consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated
Instrument type (types to be specified by each jurisdiction)	CET1 Instrument	Additional Tier 1	Additional Tier 1	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC
Amount recognised in regulatory capital (currency in million, as of most recent reporting date)	EUR 770 million	EUR 290 million	EUR 310 million	EUR 975 million	EUR 200 million	EUR 275 million	EUR 400 million	USD 300 million
Nominal amount of instrument	EUR 446 million	EUR 290 million	EUR 310 million	EUR 975 million	EUR 200 million	EUR 275 million	EUR 400 million	USD 300 million
Issue price	Various	1	1	1	1	1	1	1
Redemption price	Par	Par	Par	Par	Par	Par	Par	Par
Accounting classification	Shareholders' equity	Shareholders' equity	Shareholders' equity	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost
Original date of issuance	Various	11.06.2018	23.05.2022	27.02.2019	13.06.2022	14.05.2019	05.02.2021	03.11.2021
Perpetual or dated	Perpetual	Perpetual	Perpetual	Dated	Dated	Dated	Dated	Dated
Original maturity date	No Maturity	No Maturity	23.05.2027	27.02.2024	14.06.2027	14.05.2029	05.02.2031	03.11.2032
Issuer call subject to prior supervisory approval	N/A	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Optional call date, contingent call dates and redemption amount	N/A	11.06.2023, or earlier upon occurrence of tax or regulatory event at par value	23.05.2027, or earlier upon occurrence of tax or regulatory event at par value	At any time by giving 14 days' notice at par value	At any time by giving 14 days' notice at par value	At any time by giving 14 days' notice at par value	At any time by giving 14 days' notice at par value	At any time by giving 14 days' notice at par value
Subsequent call dates, if applicable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Coupons   dividends								
Fixed or floating dividend/coupon	Floating	Floating	Floating	Floating	Floating	Floating	Floating	Floating
Coupon rate and any related index	N/A	EURIBOR floored to zero + 466bps	3-month EURIBOR + 403bps	3-month EURIBOR floored to zero + 125bps	3-month EURIBOR + 128bps	3-month EURIBOR floored to zero + 103bps	3-month EURIBOR floored to zero + 74bps	SOFR + 134bps
Existence of a dividend stopper	No	No	No	No	No	No	No	No
Fully discretionary, partially discretionary or mandatory (in terms of timing)	Fully discretionary	Partial discretionary	Partial discretionary	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory
Fully discretionary, partially discretionary or mandatory (in terms of amount)	Fully discretionary	Partial discretionary	Partial discretionary	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory

**EU CCA: Main features of regulatory own funds instruments and eligible liabilities instruments (continued)**

	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Internal total loss-absorbing capacity (TLAC) eligible liabilities				
Existence of step up or other incentive to redeem	No	No	No	No	No	No	No	No
Noncumulative or cumulative	Non-cumulative	Non-cumulative	Non-cumulative	Non cumulative	Non cumulative	Non cumulative	Non cumulative	Non cumulative
Convertible or non-convertible	Non-convertible	Non-convertible	Non-convertible	Convertible	Convertible	Convertible	Convertible	Convertible
If convertible, conversion trigger(s)	N/A	N/A	N/A	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority
If convertible, fully or partially	N/A	N/A	N/A	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially
If convertible, conversion rate	N/A	N/A	N/A	At discretion of resolution authority	At discretion of resolution authority	At discretion of resolution authority	At discretion of resolution authority	At discretion of resolution authority
If convertible, mandatory or optional conversion	N/A	N/A	N/A	Mandatory after instruction of resolution authority	Mandatory after instruction of resolution authority	Mandatory after instruction of resolution authority	Mandatory after instruction of resolution authority	Mandatory after instruction of resolution authority
If convertible, specify instrument type convertible into	N/A	N/A	N/A	CET1	CET1	CET1	CET1	CET1
If convertible, specify issuer of instrument it converts into	N/A	N/A	N/A	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE
Write-down features	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
If write-down, write-down trigger(s)	N/A	CET1 ratio falls below 5.125%	CET1 ratio falls below 5.125%	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority
If write-down, full or partial	N/A	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially
If write-down, permanent or temporary	N/A	Temporary	Temporary	Permanent	Permanent	Permanent	Permanent	Permanent
If temporary write-down, description of write-up mechanism	N/A	Contractual conversion rate of annual balance sheet profit	Contractual conversion rate of annual balance sheet profit	N/A	N/A	N/A	N/A	N/A
Type of subordination (only for eligible liabilities)	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory
Ranking of the instrument in normal insolvency proceedings	1	2	2	5	5	5	5	5
Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	AT1	Shareholder loans	Shareholder loans	Senior non-preferred	Senior non-preferred	Senior non-preferred	Senior non-preferred	Senior non-preferred
Non-compliant transitioned features	No	No	No	No	No	No	No	No
If yes, specify non-compliant features	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Link to the full term and conditions of the instrument (signposting)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

The following table provides an overview of key metrics and the internal loss-absorbing capacity in accordance with Article 437a of the CRR.

**EU iLAC - Internal loss absorbing capacity: internal TLAC and, where applicable, requirement for own funds and eligible liabilities for non-EU G-SIIs**

	30.06.22		31.03.22	
	Non-EU G-SII Requirement for own funds and eligible liabilities (Internal TLAC)	Qualitative information	Non-EU G-SII Requirement for own funds and eligible liabilities (Internal TLAC)	Qualitative information
<i>EUR m</i>				
<b>Applicable requirement and level of application</b>				
Is the entity subject to a Non-EU G-SII Requirement for own funds and eligible liabilities? (Y/N)		Y		Y
If EU 1 is answered by 'Yes', is the requirement applicable on a consolidated or individual basis? (C/I)		C		C
Is the entity subject to an internal MREL requirement? (Y/N)		Y		Y
If EU 2a is answered by 'Yes', is the requirement applicable on a consolidated or individual basis? (C/I)		C		C
<b>Own funds and eligible liabilities</b>				
Common Equity Tier 1 capital (CET1)	2,427		2,766	
Eligible Additional Tier 1 instruments	600		290	
Eligible Tier 2 instruments				
Eligible own funds	3,027		3,056	
Eligible liabilities	2,136		1,921	
<i>of which permitted guarantees</i>				
(Adjustments)				
Own funds and eligible liabilities items after adjustments <sup>1</sup>	5,163		4,977	
<b>Total risk exposure amount and total exposure measure</b>				
Total risk exposure amount	11,412		12,275	
Total exposure measure	47,364		52,250	
<b>Ratio of own funds and eligible liabilities</b>				
Own funds and eligible liabilities (as a percentage of TREA) <sup>2</sup>	45.24%		40.55%	
<i>of which permitted guarantees</i>				
Own funds and eligible liabilities (as a percentage of leverage exposure) <sup>3</sup>	10.90%		9.53%	
<i>of which permitted guarantees</i>				
CET1 (as a percentage of TREA) available after meeting the entity's requirements	15.50%		14.65%	
Institution-specific combined buffer requirement	2.59%		2.62%	
<b>Requirements</b>				
Requirement expressed as a percentage of the total risk exposure amount	16.20%		16.20%	
<i>of which may be met with guarantees</i>				
Internal TLAC expressed as percentage of the total exposure measure	6.08%		6.08%	
<i>of which may be met with guarantees</i>				
<b>Memorandum items</b>				
Total amount of excluded liabilities referred to in Article 72a(2) CRR	22,513		29,265	

<sup>1</sup> Referred to as 'Total loss-absorbing capacity' in UBS Group report.

<sup>2</sup> Referred to as 'Total loss-absorbing capacity ratio' in UBS Group report.

<sup>3</sup> Referred to as 'Total loss-absorbing capacity leverage ratio' in UBS Group report.



The following table depicts creditor ranking of instruments in accordance with Article 437a of the CRR.

### EU TLAC2a: Creditor ranking - Entity that is not a resolution entity

30.06.22		Insolvency ranking				Total
		1 (most junior)	2	5	11	
EUR m		Resoluti- on entity	Resoluti- on entity	Resoluti- on entity	Other	Total
<b>Empty set in the EU</b>						
Description of insolvency rank	Common equity Tier 1 instruments	Additional Tier 1 instruments	Claims for repayment of shareholder loans and accrued interest thereon	Non-preferred creditor claims arising from non-subordinated, unsecured non-structured debt instruments which (i) are issued before 21 July 2018 and are neither deposits within the positions of no. 13 and 14 nor money market instruments (ii) are issued from 21 July 2018 onwards, have an original contractual maturity of at least one year, do not qualify as deposits within the position of no. 13 and 14 and the contractual documentation and, where applicable, the prospectus explicitly refer to the lower ranking		
Liabilities and own funds including derivative liabilities	2,417	600	2,139	25	5,180	
<i>of which excluded liabilities</i>			2	9	12	
Liabilities and own funds less excluded liabilities	2,417	600	2,136	15	5,168	
Subset of liabilities and own funds less excluded liabilities that are own funds and eligible liabilities for the purpose of internal TLAC	2,417	600	2,136		5,153	
<i>of which residual maturity ≥ 1 year &lt; 2 years</i>			975		975	
<i>of which residual maturity ≥ 2 year &lt; 5 years</i>						
<i>of which residual maturity ≥ 5 years &lt; 10 years</i>			1,161		1,161	
<i>of which residual maturity ≥ 10 years, but excluding perpetual securities</i>						
<i>of which perpetual securities</i>	2,417	600			3,017	
<b>31.12.21</b>						
31.12.21		Insolvency ranking				Total
		1 (most junior)	2	5	11	
EUR m		Resoluti- on entity	Resoluti- on entity	Resoluti- on entity	Other	Total
<b>Empty set in the EU</b>						
Description of insolvency rank	Common equity Tier 1 instruments	Additional Tier 1 instruments	Claims for repayment of shareholder loans and accrued interest thereon	Non-preferred creditor claims arising from non-subordinated, unsecured non-structured debt instruments which (i) are issued before 21 July 2018 and are neither deposits within the positions of no. 13 and 14 nor money market instruments (ii) are issued from 21 July 2018 onwards, have an original contractual maturity of at least one year, do not qualify as deposits within the position of no. 13 and 14 and the contractual documentation and, where applicable, the prospectus explicitly refer to the lower ranking		
Liabilities and own funds including derivative liabilities	2,753	290	2,415	33	5,491	
<i>of which excluded liabilities</i>			2	14	16	
Liabilities and own funds less excluded liabilities	2,753	290	2,414	19	5,476	
Subset of liabilities and own funds less excluded liabilities that are own funds and eligible liabilities for the purpose of internal TLAC	2,753	290	2,414		5,457	
<i>of which residual maturity ≥ 1 year &lt; 2 years</i>			500		500	
<i>of which residual maturity ≥ 2 year &lt; 5 years</i>			975		975	
<i>of which residual maturity ≥ 5 years &lt; 10 years</i>			939		939	
<i>of which residual maturity ≥ 10 years, but excluding perpetual securities</i>						
<i>of which perpetual securities</i>	2,753	290			3,043	

## Covid-19 Disclosures

The following table provides an overview of the credit quality of loans and advances subject to moratoria on loan repayments applied in the light of the COVID-19 crisis, in accordance with EBA/GL/2020/02.

Application of moratoria is on a case by case basis on own merits. Usually involves extension of bullet mortgage (with continued payment of interest) or if under legislative moratoria - suspension of capital and interest payments. There have been no economic losses or provisions so far.

### Covid-19 Template 1: Information on loans and advances subject to legislative and non-legislative moratoria

30.06.22	Gross carrying amount		Accumulated impairment, accumulated negative changes in fair value due to credit risk				Gross carrying amount		
	Performing		Non performing		Performing			Non performing	
	Of which: exposures with forbearance measures	Of which: Instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)	Of which: exposures with forbearance measures	Of which: Unlikely to pay that are not past-due or past-due <= 90 days	Of which: exposures with forbearance measures	Of which: Instruments with significant increase in credit risk since initial recognition but not credit-impaired (Stage 2)		Of which: exposures with forbearance measures	Of which: Unlikely to pay that are not past-due or past-due <= 90 days
<i>EUR m</i>								Inflows to non-performing exposures	
Loans and advances subject to moratorium	2	2							
<i>of which: Households</i>									
<i>of which: Collateralised by residential immovable property</i>									
<i>of which: Non-financial corporations</i>	2	2							
<i>of which: Small and Medium-sized Enterprises</i>									
<i>of which: Collateralised by commercial immovable property</i>	2	2							
31.12.21									
<i>EUR m</i>								Inflows to non-performing exposures	
Loans and advances subject to moratorium	2	2							
<i>of which: Households</i>									
<i>of which: Collateralised by residential immovable property</i>									
<i>of which: Non-financial corporations</i>	2	2							
<i>of which: Small and Medium-sized Enterprises</i>									
<i>of which: Collateralised by commercial immovable property</i>	2	2							

The following table provides an overview of the volume of loans and advances subject to legislative and non-legislative moratoria in accordance with EBA/GL/2020/02 by residual maturity of these moratoria.

Length of the moratoria is agreed on a case by case basis with the client based on the merits of the case. For legislative moratoria we are bound by the government laws. Further extensions would also be agreed on a case by cases basis.

### Covid-19 Template 2: Breakdown of loans and advances subject to legislative and non-legislative moratoria by residual maturity of moratoria

EUR m	Number of obligors	Gross carrying amount					
		Of which: legislative moratoria	Of which: expired	Residual maturity of moratoria			
				<= 3 months	> 3 months <= 6 months	> 6 months <= 9 months	> 1 year
Loans and advances for which moratorium was offered	10	2					
Loans and advances subject to moratorium (granted)	6	2	2	2			
<i>of which: Households</i>							
<i>of which: Collateralised by residential immovable property</i>							
<i>of which: Non-financial corporations</i>		2	2	2			
<i>of which: Small and Medium-sized Enterprises</i>							
<i>of which: Collateralised by commercial immovable property</i>		2	2	2			
<hr/>							
31.12.21	Gross carrying amount						
EUR m	Number of obligors	Of which: legislative moratoria	Of which: expired	Residual maturity of moratoria			
				<= 3 months	> 3 months <= 6 months	> 6 months <= 9 months	> 1 year
Loans and advances for which moratorium was offered	11	3					
Loans and advances subject to moratorium (granted)	7	2	2	2			
<i>of which: Households</i>							
<i>of which: Collateralised by residential immovable property</i>							
<i>of which: Non-financial corporations</i>		2	2	2			
<i>of which: Small and Medium-sized Enterprises</i>							
<i>of which: Collateralised by commercial immovable property</i>		2	2	2			

As of 30 June 2022, there were no newly originated loans and advances subject to public guarantee schemes introduced in response to COVID-19 crisis.

# Contacts

Should you have any queries please contact the UBS Investor Relations team:

UBS Group AG  
Investor Relations  
P.O. Box  
CH-8098 Zurich  
Switzerland

Tel: +41-44-234 4100

Email: [sh-investorrelations@ubs.com](mailto:sh-investorrelations@ubs.com)

[ubs.com/investors](https://ubs.com/investors)

UBS Europe SE is a Societas Europaea registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Frankfurt am Main under HRB 107046. Registered business address: Bockenheimer Landstraße 2-4, Operturm, 60306 Frankfurt am Main. The Chairman of Supervisory Board of UBS Europe SE is Prof. Dr. Reto Francioni. The Management Board of UBS Europe SE is composed of Christine Novakovic (Chair), Heinrich Baer, Dr. Denise Bauer-Weiler, Pierre Chavenon, Georgia Paphiti, Tobias Vogel.

UBS Europe SE is a subsidiary of UBS Group AG.

This document may contain statements that constitute “forward looking statements” including but not limited to statements relating to the anticipated effect of transactions described herein and other risks specific to UBS’s business, strategic initiatives, future business development and economic performance. While these forward-looking statements represent UBS’s judgements and expectations concerning the development of its business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from UBS’s expectations.

This document is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to. It should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this material are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Neither UBS nor any of its affiliates, nor any of UBS’ or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material.

In this disclaimer UBS means UBS Group AG, UBS AG and UBS Europe SE.

The information contained within this document has not been audited by the external auditors of UBS Europe SE.

Numbers presented throughout this report may not add up precisely to the totals provided in the tables and text due to rounding.

[ubs.com](https://ubs.com)

